The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.

Published Date: 08 Apr 2024

In three trials, the response rate was about half the patients, and it lasted for up to 19 months.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Modified personalized cancer vaccine generates powerful immune response

2.

Is There a Role for Stimulants in Beating Cancer Fatigue?

3.

HER2 ADC Shows Promise in Recurrent Endometrial Cancer

4.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

5.

According to JAMA, even four minutes a day of exercise can lower the risk of cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot